“Topical Axitinib Combined with Rapamycin to Inhibit the Regrowth of Port Wine Stain Blood Vessels Post Pulsed Dye Laser Treatment ”
The pulsed dye laser (PDL) is the current treatment of choice for Port Wine Stain (PWS), but the therapeutic outcome is inadequate due to the reformation and reperfusion of PWS blood vessels. We herein propose that combination of two anti-angiogenesis agents, rapamycin (RPM) and axitinib, should inhibit multiple angiogenesis pathways, including blockage of phosphorylation of VEGFRs and PDGFR and phosphoinositide 3-kinase / AKT / the mammalian target of rapamycin (PI3K/AKT/mTOR), thus leading to an effective inhibition of regrowth of blood vessels post PDL.
“Catheter-Based Combined OCT and Two-Photon Luminescence Imaging System for Detection of Thincap Fibroatheroma ”
Atherosclerosis and plaque rupture leading to myocardial infarction, stroke and progression of peripheral artery disease remain the leading cause of death worldwide. The proposed project is to construct a catheter-based combined OCT-TPL imaging system to simultaneously detect structure and composition of thin-cap fibroatheromas. The catheter-based OCT-TPL system incorporates spectral-domain OCT (1310 nm), TPL imaging (at 760-1040 nm excitation) and a catheter that combine both. A dispersion compressor is utilized to provide transform-limited pulses. A photonic crystal fiber (PCF) is used to transmit single-mode OCT and TPL light simultaneously to/from the sample. TPL emission signals are directed into photomultiplier tubes (PMT1: 640-720nm; PMT2: <570nm) to distinguish macrophages (loaded with nanoparticles) and other plaque components (e.g., elastin fibers and lipid deposits). Successful completion of the proposed study will establish a novel imaging approach to simultaneously detect plaque structure and composition, and will motivate other application possibilities such as tumor-associated macrophage detection in
external and internal cancers (e.g., cutaneous melanoma, breast, prostate, ovarian, cervical
and colon cancers).